Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.


GREY:ATNXQ - Post by User

Athenex Inc > ATNX & CHMA............
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(69)
•••
Post by Iseneschalon May 05, 2021 12:35pm
108 Views
Post# 33132659

ATNX & CHMA............

ATNX & CHMA............Check my charts out..........see the similarities ?

ATNX  https://invst.ly/uoyji

CHMA  https://invst.ly/uoyk1

THis is why I use Stop losses regularly


 Cheers .....conversely take a look at NMRD.......I just scalped it for about $500

NMRD  https://invst.ly/uoyl6


Ya win some ....and u lose some...just make sure your losses are small
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities